U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Management of Physical Health Conditions in Adults with Severe Mental Disorders. Geneva: World Health Organization; 2018.

Cover of Management of Physical Health Conditions in Adults with Severe Mental Disorders

Management of Physical Health Conditions in Adults with Severe Mental Disorders.

Show details

References

  • Alene, K. A. et al. (2018) ‘Mental health disorders, social stressors, and health-related quality of life in patients with multidrug-resistant tuberculosis: A systematic review and meta-analysis’, Journal of Infection. Elsevier. doi: 10.1016/j.jinf.2018.07.007. [PubMed: 30036607] [CrossRef]
  • Alipanah, N. et al. (2018) Adherence interventions and outcomes of tuberculosis treatment: A systematic review and meta-analysis of trials and observational studies, PLOS Medicine. doi: 10.1371/journal.pmed.1002595. [PMC free article: PMC6029765] [PubMed: 29969463] [CrossRef]
  • Alonso-Coello, P. et al. (2016) ‘GRADE Evidence to Decision (EtD) frameworks: a systematic and transparent approach to making well informed healthcare choices. 1: Introduction’, BMJ. BMJ Publishing Group Ltd, 353. doi: 10.1136/bmj.i2016. [PubMed: 27353417] [CrossRef]
  • Anthenelli, R. M. et al. (2016) ‘Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial’, The Lancet. Elsevier, 387(10037), pp. 2507–2520. doi: 10.1016/S0140-6736(16)30272-0. [PubMed: 27116918] [CrossRef]
  • Barnes, T. R. E. et al. (2007) ‘A UK audit of screening for the metabolic side effects of antipsychotics in community patients.’, Schizophrenia bulletin. Oxford University Press, 33(6), pp. 1397–403. doi: 10.1093/schbul/sbm038. [PMC free article: PMC2779874] [PubMed: 17483101] [CrossRef]
  • Bauer-Staeb, C. et al. (2017) ‘Prevalence and risk factors for HIV, hepatitis B, and hepatitis C in people with severe mental illness: a total population study of Sweden’, The Lancet Psychiatry. Elsevier, 4(9), pp. 685–693. doi: 10.1016/S2215-0366(17)30253-5. [PMC free article: PMC5573766] [PubMed: 28687481] [CrossRef]
  • Camilloni, L. et al. (2013) ‘Methods to increase participation in organised screening programs: a systematic review’, BMC Public Health, 13(1), p. 464. doi: 10.1186/1471-2458-13-464. [PMC free article: PMC3686655] [PubMed: 23663511] [CrossRef]
  • Capasso, R. M. et al. (2008) ‘Mortality in schizophrenia and schizoaffective disorder: An Olmsted County, Minnesota cohort: 1950–2005’, Schizophrenia Research. Elsevier, 98(1–3), pp. 287–294. doi: 10.1016/J.SCHRES.2007.10.005. [PubMed: 18031996] [CrossRef]
  • Centers for Disease Control and Prevention (2015) ‘Best Practices User Guide: Health Equity in Tobacco Prevention and Control’, pp. 1–52. Available at: https://www​.cdc.gov/tobacco​/stateandcommunity​/best-practices-health-equity/pdfs/.
  • Chou, R.-H. et al. (2017) ‘Antipsychotic treatment is associated with risk of atrial fibrillation: A nationwide nested case-control study.’, International journal of cardiology. Elsevier, 227, pp. 134–140. doi: 10.1016/j.ijcard.2016.11.185. [PubMed: 27855291] [CrossRef]
  • Correll, C. U. et al. (2015) ‘Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder’, World Psychiatry, 14, pp. 119–136. doi: 10.1002/wps.20204. [PMC free article: PMC4471960] [PubMed: 26043321] [CrossRef]
  • Correll, C. U. et al. (2017) ‘Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large‐scale meta‐analysis of 3,211,768 patients and 113,383,368 controls’, World Psychiatry, 16, pp. 163–180. [PMC free article: PMC5428179] [PubMed: 28498599]
  • Dennis, B. B. et al. (2015) ‘Opioid substitution and antagonist therapy trials exclude the common addiction patient: a systematic review and analysis of eligibility criteria’, Trials. London. doi: 10.1186/s13063-015-0942-4. [PMC free article: PMC4618532] [PubMed: 26489415] [CrossRef]
  • Dickerson, F. B. et al. (2006) ‘Obesity among individuals with serious mental illness’, Acta Psychiatrica Scandinavica, 113(4), pp. 306–313. doi: 10.1111/j.1600-0447.2005.00637.x. [PubMed: 16638075] [CrossRef]
  • Dipasquale, S. et al. (2013) ‘The dietary pattern of patients with schizophrenia: A systematic review’, Journal of Psychiatric Research. Pergamon, 47(2), pp. 197–207. doi: 10.1016/J.JPSYCHIRES.2012.10.005. [PubMed: 23153955] [CrossRef]
  • Druss, B. G. et al. (2000) ‘Mental Disorders and Use of Cardiovascular Procedures After Myocardial Infarction’, JAMA. American Medical Association, 283(4), p. 506. doi: 10.1001/jama.283.4.506. [PubMed: 10659877] [CrossRef]
  • Fekadu, A. et al. (2015) ‘Excess mortality in severe mental illness: 10-Year population-based cohort study rural Ethiopia’, British Journal of Psychiatry, 206(4), pp. 289–296. doi: 10.1192/bjp.bp.114.149112. [PubMed: 25657358] [CrossRef]
  • Di Florio, A., Craddock, N. and van den Bree, M. (2014) ‘Alcohol misuse in bipolar disorder. A systematic review and meta-analysis of comorbidity rates’, European Psychiatry. Elsevier, 29(3), pp. 117–124. doi: 10.1016/j.eurpsy.2013.07.004. [PubMed: 24075633] [CrossRef]
  • Gates, P. J. et al. (2016) ‘Psychosocial interventions for cannabis use disorder’, The Cochrane database of systematic reviews, p. CD005336. doi: 10.1002/14651858.CD005336.pub4. [PMC free article: PMC4914383] [PubMed: 27149547] [CrossRef]
  • Gierisch, J. M. et al. (2013) Interventions To Improve Cardiovascular Risk Factors in People With Serious Mental Illness, AHRQ Comparative Effectiveness Reviews. Available at: http://www​.epistemonikos​.org/documents/2a89f84579c968376a0ebb29ce11b78b2943d82f [PubMed: 23700634]
  • Gurpegui, M. et al. (2012) ‘Overweight and obesity in patients with bipolar disorder or schizophrenia compared with a non-psychiatric sample’, Progress in Neuro-Psychopharmacology and Biological Psychiatry. Elsevier, 37(1), pp. 169–175. doi: 10.1016/J.PNPBP.2012.01.014. [PubMed: 22326681] [CrossRef]
  • Guyatt, G. et al. (2011) ‘GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables’, Journal of Clinical Epidemiology. Pergamon, 64(4), pp. 383–394. doi: 10.1016/J.JCLINEPI.2010.04.026. [PubMed: 21195583] [CrossRef]
  • Henderson, D. C. et al. (2005) ‘Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study.’, The Journal of clinical psychiatry, 66(9), pp. 1116–21. [PubMed: 16187768]
  • De Hert, M. et al. (2011) ‘Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care’, World Psychiatry, 10(1), pp. 52–77. [PMC free article: PMC3048500] [PubMed: 21379357]
  • Hjorthøj, C. et al. (2015) ‘Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study’, The Lancet Psychiatry, 2(9), pp. 801–808. doi: 10.1016/S2215-0366(15)00207-2. [PubMed: 26277044] [CrossRef]
  • Hughes, E. et al. (2016) ‘Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness: a systematic review and meta-analysis’, The Lancet Psychiatry. Elsevier, 3(1), pp. 40–48. doi: 10.1016/S2215-0366(15)00357-0. [PMC free article: PMC4703902] [PubMed: 26620388] [CrossRef]
  • Hunt, G. E. et al. (2014) ‘Psychosocial interventions for people with both severe mental illness and substance misuse’, Schizophr Bull. 2013/11/02 [PMC free article: PMC3885307] [PubMed: 24179148]
  • Jackson, J. G. et al. (2015) ‘A combined analysis of worldwide studies demonstrates an association between bipolar disorder and tobacco smoking behaviors in adults’, Bipolar Disorders, 17(6), pp. 575–597. doi: 10.1111/bdi.12319. [PubMed: 26238269] [CrossRef]
  • Jakobsen, A. S. et al. (2018) ‘Dietary patterns and physical activity in people with schizophrenia and increased waist circumference’, Schizophrenia Research. Elsevier. doi: 10.1016/J.SCHRES.2018.03.016. [PubMed: 29555213] [CrossRef]
  • Janney, C. A. (2013) ‘Sedentary behavior and psychiatric symptoms in overweight and obese adults with schizophrenia and schizoaffective disorders (WAIST Study)’. doi: 10.1016/j.schres.2013.01.010. [PMC free article: PMC3836608] [PubMed: 23410710] [CrossRef]
  • Janssen, E. M. et al. (2015) ‘Review of the Evidence: Prevalence of Medical Conditions in the United States Population with Serious Mental Illness’, General hospital psychiatry, pp. 199–222. doi: 10.1016/j.genhosppsych.2015.03.004. [PMC free article: PMC4663043] [PubMed: 25881768] [CrossRef]
  • Jørgensen, K. B., Nordentoft, M. and Hjorthøj, C. (2018) ‘Association between alcohol and substance use disorders and psychiatric service use in patients with severe mental illness: a nationwide Danish register-based cohort study’, Psychological Medicine. Cambridge University Press, pp. 1–9. doi: 10.1017/S0033291718000223. [PubMed: 29429425] [CrossRef]
  • Kakuma, R. et al. (2011) ‘Human resources for mental health care: current situation and strategies for action’, The Lancet. Elsevier, 378(9803), pp. 1654–1663. doi: 10.1016/S0140-6736(11)61093-3. [PubMed: 22008420] [CrossRef]
  • Kapczinski, F. et al. (2008) ‘Allostatic load in bipolar disorder: Implications for pathophysiology and treatment’, Neuroscience & Biobehavioral Reviews. Pergamon, 32(4), pp. 675–692. doi: 10.1016/J.NEUBIOREV.2007.10.005. [PubMed: 18199480] [CrossRef]
  • Kreyenbuhl, J. et al. (2010) ‘The Schizophrenia Patient Outcomes Research Team (PORT): Updated Treatment Recommendations 2009’, Schizophrenia Bulletin. Oxford University Press, 36(1), pp. 94–103. doi: 10.1093/schbul/sbp130. [PMC free article: PMC2800150] [PubMed: 19955388] [CrossRef]
  • Krupchanka, D. et al. (2018) ‘Mortality in people with mental disorders in the Czech Republic: a nationwide, register-based cohort study’, The Lancet Public Health, 3(6), pp. e289–e295. doi: 10.1016/S2468-2667(18)30077-X. [PubMed: 29884434] [CrossRef]
  • Kuo, S.-C. et al. (2013) ‘Incidence and outcome of newly-diagnosed tuberculosis in schizophrenics: a 12-year, nationwide, retrospective longitudinal study’, BMC Infectious Diseases. BioMed Central, 13(1), p. 351. doi: 10.1186/1471-2334-13-351. [PMC free article: PMC3729604] [PubMed: 23895638] [CrossRef]
  • Lamontagne-Godwin, F. et al. (2018) ‘Interventions to increase access to or uptake of physical health screening in people with severe mental illness: a realist review’, BMJ Open. British Medical Journal Publishing Group, 8(2). doi: 10.1136/bmjopen-2017-019412. [PMC free article: PMC5829934] [PubMed: 29440160] [CrossRef]
  • Lasser, K. et al. (2000) ‘Smoking and Mental Illness’, JAMA. American Medical Association, 284(20), p. 2606. doi: 10.1001/jama.284.20.2606. [PubMed: 11086367] [CrossRef]
  • Laursen, T. M. (2011) ‘Life expectancy among persons with schizophrenia or bipolar affective disorder’, Schizophrenia Research. Elsevier, 131(1–3), pp. 101–104. doi: 10.1016/J.SCHRES.2011.06.008. [PubMed: 21741216] [CrossRef]
  • de Leon, J. and Diaz, F. J. (2005) ‘A meta-analysis of worldwide studies demonstrates an association between schizophrenia and tobacco smoking behaviors’, Schizophrenia Research. Elsevier, 76(2–3), pp. 135–157. doi: 10.1016/J.SCHRES.2005.02.010. [PubMed: 15949648] [CrossRef]
  • Li, C. et al. (2017) ‘A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for patients with diabetes and depression’, Journal of Psychosomatic Research. [PubMed: 28314548]
  • Lieberman, J. A. et al. (2005) ‘Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia’, New England Journal of Medicine. Massachusetts Medical Society, 353(12), pp. 1209–1223. doi: 10.1056/NEJMoa051688. [PubMed: 16172203] [CrossRef]
  • Liu, N. H. et al. (2017) ‘Excess mortality in persons with severe mental disorders: a multilevel intervention framework and priorities for clinical practice, policy and research agendas.’, World psychiatry. World Psychiatric Association, 16(1), pp. 30–40. doi: 10.1002/wps.20384. [PMC free article: PMC5269481] [PubMed: 28127922] [CrossRef]
  • Lund, C. et al. (2013) ‘Mental illness and lost income among adult South Africans’, Social Psychiatry and Psychiatric Epidemiology, 48(5), pp. 845–851. doi: 10.1007/s00127-012-0587-5. [PMC free article: PMC3627034] [PubMed: 23007296] [CrossRef]
  • Mangurian, C. et al. (2017) ‘Low Rates of HIV Testing Among Adults With Severe Mental Illness Receiving Care in Community Mental Health Settings’, Psychiatric Services, 68(5), pp. 443–448. doi: 10.1176/appi.ps.201600248. [PubMed: 28093055] [CrossRef]
  • Maslej, M. M. et al. (2017) ‘The Mortality and Myocardial Effects of Antidepressants Are Moderated by Preexisting Cardiovascular Disease: A Meta-Analysis’, Psychotherapy and Psychosomatics. [PubMed: 28903117]
  • Mattick, R. P. et al. (2014) Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence’, The Cochrane database of systematic reviews, 2(2), p. CD002207. doi: 10.1002/14651858.CD002207.pub4.Copyright. [PMC free article: PMC10617756] [PubMed: 24500948] [CrossRef]
  • McLoughlin, B. C. et al. (2014) ‘Cannabis and schizophrenia’, Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, (10). doi: 10.1002/14651858.CD004837.pub3. [PMC free article: PMC10107010] [PubMed: 25314586] [CrossRef]
  • Morrato, E. H. et al. (2009) ‘Metabolic Screening After the American Diabetes Association’s Consensus Statement on Antipsychotic Drugs and Diabetes’, Diabetes Care, 32(6), pp. 1037–1042. doi: 10.2337/dc08-1720. [PMC free article: PMC2681020] [PubMed: 19244091] [CrossRef]
  • Naslund, J. A. et al. (2017) ‘Lifestyle interventions for weight loss among overweight and obese adults with serious mental illness: A systematic review and meta-analysis’, General Hospital Psychiatry. [PMC free article: PMC5575752] [PubMed: 28807143]
  • NICE guidelines. Psychosis and schizophrenia in adults: prevention and management (Clinical guideline [CG178]; Published date: February 2014 Last updated: March 2014.
  • NICE guidelines Bipolar disorder: assessment and management (Clinical guideline [CG185]; Published date: September 2014 Last updated: February 2016.
  • NICE guidelines Depression in adults with a chronic physical health problem: recognition and management (Clinical guideline [CG91]; Published date: October 2009.
  • Nielsen, R. E. et al. (2013) ‘Increasing mortality gap for patients diagnosed with schizophrenia over the last three decades — A Danish nationwide study from 1980 to 2010’, Schizophrenia Research. Elsevier, 146(1–3), pp. 22–27. doi: 10.1016/J.SCHRES.2013.02.025. [PubMed: 23523021] [CrossRef]
  • Nieuwsma, J. A. et al. (2017) ‘Diagnostic accuracy of screening tests and treatment for post-acute coronary syndrome depression’, Annals of Internal Medicine. [PubMed: 29132152]
  • Nugent, K. L. et al. (2015) ‘Cumulative stress pathophysiology in schizophrenia as indexed by allostatic load.’, Psychoneuroendocrinology. NIH Public Access, 60, pp. 120–9. doi: 10.1016/j.psyneuen.2015.06.009. [PMC free article: PMC4526449] [PubMed: 26142568] [CrossRef]
  • Patel, M. X. et al. (2014) ‘Quality of prescribing for schizophrenia: Evidence from a national audit in England and Wales’, European Neuropsychopharmacology, 24(4), pp. 499–509. doi: 10.1016/j.euroneuro.2014.01.014. [PubMed: 24491953] [CrossRef]
  • Poon, A. W. C. et al. (2017) ‘A longitudinal population-based study of carers of people with psychosis’, Epidemiology and Psychiatric Sciences. Cambridge University Press, 26(3), pp. 265–275. doi: 10.1017/S2045796015001195. [PMC free article: PMC6998635] [PubMed: 26847994] [CrossRef]
  • Rosenberg, S. D. et al. (2010) ‘Assessing the STIRR Model of Best Practices for Blood-Borne Infections of Clients With Severe Mental Illness’, Psychiatric Services, 61(9), pp. 885–891. doi: 10.1176/ps.2010.61.9.885. [PMC free article: PMC3632357] [PubMed: 20810586] [CrossRef]
  • Sacchetti, E., Turrina, C. and Valsecchi, P. (2010) ‘Cerebrovascular accidents in elderly people treated with antipsychotic drugs: a systematic review’, Drug Saf., 33(4), pp. 273–288. doi: 2 [pii] 10.2165/11319120-000000000-00000. [PubMed: 20297860] [CrossRef]
  • Saha, S., Chant, D. and McGrath, J. (2007) ‘A systematic review of mortality in Schizophrenia: is the differential mortality gap worsening over time?’, Archives of General Psychiatry, 64(10), pp. 1123–31. doi: 10.1001/archpsyc.64.10.1123. [PubMed: 17909124] [CrossRef]
  • Saloojee, S., Burns, J. K. and Motala, A. A. (2014) ‘Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa’, BMC Psychiatry, 14(1), p. 228. doi: 10.1186/s12888-014-0228-5. [PMC free article: PMC4149236] [PubMed: 25113131] [CrossRef]
  • Senn, T. E. and Carey, M. P. (2009) ‘HIV testing among individuals with a severe mental illness: review, suggestions for research, and clinical implications’, Psychological Medicine, 39(03), p. 355. doi: 10.1017/S0033291708003930. [PMC free article: PMC2640447] [PubMed: 18606051] [CrossRef]
  • de Silva, V. A. et al. (2016) ‘Metformin in prevention and treatment of antipsychotic induced weight gain: a systematic review and meta-analysis’, BMC Psychiatry. 2016/10/08. [PMC free article: PMC5048618] [PubMed: 27716110]
  • Ski, C. F. et al. (2016) ‘Psychosocial interventions for patients with coronary heart disease and depression: A systematic review and meta-analysis’, European Journal of Cardiovascular Nursing. [PubMed: 26475227]
  • Susser, E., Valencia, E. and Conover, S. (1993) ‘Prevalence of HIV infection among psychiatric patients in a New York City men’s shelter.’, American Journal of Public Health, pp. 568–570. [PMC free article: PMC1694479] [PubMed: 8460736]
  • Taylor, J. et al. (2017) ‘The Effectiveness of Pharmacological and Non-Pharmacological Interventions for Improving Glycaemic Control in Adults with Severe Mental Illness: A Systematic Review and Meta-Analysis’, PLoS One. [PMC free article: PMC5215855] [PubMed: 28056018]
  • Teasdale, S. B. et al. (2017) ‘Solving a weighty problem: systematic review and meta-analysis of nutrition interventions in severe mental illness’, Br J Psychiatry. [PubMed: 27810893]
  • Temmingh, H. S. et al. (2018) ‘Risperidone versus other antipsychotics for people with severe mental illness and co-occurring substance misuse’, Cochrane Database of Systematic Reviews. [PMC free article: PMC6491096] [PubMed: 29355909]
  • Trainor, K. and Leavey, G. (2017) ‘Barriers and Facilitators to Smoking Cessation Among People With Severe Mental Illness: A Critical Appraisal of Qualitative Studies’, Nicotine & Tobacco Research, 19(1), pp. 14–23. doi: 10.1093/ntr/ntw183. [PubMed: 27613905] [CrossRef]
  • Tsuang, M. T., Woolson, R. F. and Fleming, J. A. (1980) ‘Premature Deaths in Schizophrenia and Affective Disorders’, Archives of General Psychiatry. American Medical Association, 37(9), p. 979. doi: 10.1001/archpsyc.1980.01780220017001. [PubMed: 7416910] [CrossRef]
  • Tully, P. J. and Baumeister, H. (2015) ‘Collaborative care for comorbid depression and coronary heart disease: A systematic review and meta-analysis of randomised controlled trials’, BMJ Open. [PMC free article: PMC4691772] [PubMed: 26692557]
  • United Nations (2016) Annex IV: Final list of proposed Sustainable Development Goal indicators. Report of the Inter-Agency and Expert Group on Sustainable Development Goal Indicators.
  • Vahdat, S. et al. (2014) ‘Patient Involvement in Health Care Decision Making: A Review’, Iranian Red Crescent Medical Journal. doi: 10.5812/ircmj.12454. [PMC free article: PMC3964421] [PubMed: 24719703] [CrossRef]
  • Vancampfort, D. et al. (2016) ‘Diabetes mellitus in people with schizophrenia, bipolar disorder and major depressive disorder: A systematic review and large scale meta-analysis’, World Psychiatry, 15(2), pp. 166–174. doi: 10.1002/wps.20309. [PMC free article: PMC4911762] [PubMed: 27265707] [CrossRef]
  • Vancampfort, D. et al. (2017) ‘Sedentary behavior and physical activity levels in people with schizophrenia, bipolar disorder and major depressive disorder: a global systematic review and meta-analysis.’, World psychiatry. World Psychiatric Association, 16(3), pp. 308–315. doi: 10.1002/wps.20458. [PMC free article: PMC5608847] [PubMed: 28941119] [CrossRef]
  • Verschueren, S. et al. (2018) ‘The effect of exercise therapy on depressive and anxious symptoms in patients with ischemic heart disease: A systematic review’, Journal of Psychosomatic Research. [PubMed: 29332638]
  • Watson, K. et al. (2017) ‘Insulin resistance, an unmasked culprit in depressive disorders: Promises for interventions’, Neuropharmacology. Pergamon. doi: 10.1016/J.NEUROPHARM.2017.11.038. [PubMed: 29180223] [CrossRef]
  • Whiteford, H. A. et al. (2015) ‘The Global Burden of Mental, Neurological and Substance Use Disorders: An Analysis from the Global Burden of Disease Study 2010’, PLoS ONE, 10(2). doi: 10.1371/journal.pone.0116820. [PMC free article: PMC4320057] [PubMed: 25658103] [CrossRef]
  • WHO. (2008) WHO Report on the Global Tobacco Epidemic 2008: the MPOWER Package. World Health Organization.
  • Wilson, R. P. and Bhattacharyya, S. (2016) ‘Antipsychotic efficacy in psychosis with co-morbid cannabis misuse: A systematic review’, J Psychopharmacol. [PubMed: 26510450]
  • World Health Organization (2013) Mental Health Action Plan (2013–2020).
  • World Health Organization (2015) Meeting report on excess mortality in persons with severe mental disorders.
  • World Health Organization Regional Office for Europe (2016) Addressing comorbidity between mental disorders and major noncommunicable diseases.
  • Yang, C. et al. (2018) ‘Does antipsychotic drug use increase the risk of long term mortality? A systematic review and meta-analysis of observational studies.’, Oncotarget. Impact Journals, LLC, 9(19), pp. 15101–15110. doi: 10.18632/oncotarget.24120. [PMC free article: PMC5871101] [PubMed: 29599930] [CrossRef]
© World Health Organization 2018.

Sales, rights and licensing. To purchase WHO publications, see http://apps.who.int/bookorders. To submit requests for commercial use and queries on rights and licensing, see http://www.who.int/about/licensing.

Third-party materials. If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”.

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

Bookshelf ID: NBK534477

Views

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to PubMed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...